An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

Ireland News News

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19
Ireland Latest News,Ireland Headlines
  • 📰 ScienceMagazine
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 63%

A new Science study details PF-07321332, an orally active, small-molecule inhibitor of the SARSCoV2 main protease, a key viral target. In a phase I clinical trial, it achieved concentrations expected to inhibit the virus based on in vitro studies. pfizer

=90.5 ng/ml, 181 nM) at 12 hours after dose, thus increasing confidence in achieving robust pan-coronavirus antiviral activity clinically . On the basis of these observations and the high safety margins at the NOAEL doses in animals, the efficacy of PF-07321332 in COVID-19 patients will be assessed with a twice-daily dosing paradigm with the potential to increase the dose of PF-07321332 as a single agent and/or co-administered with RTV.

This research used resources of the Advanced Photon Source, a US Department of Energy Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract no. DE-AC02-06CH11357. Extraordinary facility operations were supported in part by the DOE Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE national laboratories focused on the response to COVID-19, with funding provided by the Coronavirus CARES Act.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

ScienceMagazine /  🏆 285. in US

Ireland Latest News, Ireland Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

A new tool to probe SARS-CoV-2 variantsA new tool to probe SARS-CoV-2 variantsVirus-like particles offer a new way to investigate genetic variation in SARSCoV2. Learn more in a new SciencePerspective:
Read more »

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shiftNature research paper: Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Read more »

New easy-to-use COVID-19 pills come with a catchNew easy-to-use COVID-19 pills come with a catchNewly infected COVID-19 patients have two new treatment options that can be taken at home. But that convenience comes with a catch: The pills have to be taken as soon as possible once symptoms appear.
Read more »

EXPLAINER: New Easy-to-Use COVID-19 Pills Come With a CatchEXPLAINER: New Easy-to-Use COVID-19 Pills Come With a CatchNewly infected COVID-19 patients have two new treatment options that can be taken at home. But that convenience comes with a catch: The pills have to be taken as soon as possible once symptoms appear.
Read more »

New easy-to-use COVID-19 pills come with a catchNew easy-to-use COVID-19 pills come with a catchNewly infected COVID-19 patients have two new treatment options that can be taken at home.
Read more »

EXPLAINER: New easy-to-use COVID-19 pills come with a catchEXPLAINER: New easy-to-use COVID-19 pills come with a catchNewly infected COVID-19 patients have two new treatment options that can be taken at home, but the pills have to be taken as soon as possible once symptoms appear.
Read more »



Render Time: 2025-03-13 01:02:42